Sinopharm - China National Pharmaceutical Group Corporation
We -China National Pharmaceutical Group Corporation (Sinopharm)- are the largest Chinese medical and healthcare group directly managed by State-owned Assets Supervision and Administration Commission of the State Council (SASAC), with the most complete industrial chain coverage and strongest comprehensive competence in China.
Our core businesses include distribution, retail, scientific research and manufacture of healthcare related products and we own 11 wholly-owned or holding subsidiaries, and 6 listed companies: Sinopharm Group Co., Ltd., China National Medicines Co., Ltd., Sinopharm Accord Medicines Co., Ltd., Beijing Tiantan Biological Products Co., Ltd., Shanghai Shyndec Pharmaceutical Co., Ltd. and China Traditional Chinese Medicine Co. Ltd..
Since Year 2003 to Year 2013, our annual average growth rate of revenue was 31%, annual average growth rate of gross profit was 42% and annual average growth rate of total assets was 32%.
In 2013, our sales revenue exceeded RMB 200 billion and became the first Chinese pharmaceutical company who entered Global Top 500. We rank the 357th in Fortune Magazine top 500 2014 and the 8th place among all pharmaceutical enterprises on the list.